Navegando por Palavras-chave "hormone therapy"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)Análise de polimorfismo nos genes do receptor de estrogênio alpha – ERα (HaeIII e MspI) em mulheres em terapia substitutiva com estrogênios(Universidade Federal de São Paulo (UNIFESP), 2014-06-25) Taborda, Ana Maria de Oliveira [UNIFESP]; Silva, Ismael Dale Cotrim Guerreiro da [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Introduction: The increase of the life expectancy in the last 60 years, makes women spend one-third of their lifetime in climacteric period. The hormonal replacement in the post-menopause, seems to bring many benefits such as improvement of the vasomotor symptoms, cardiovascular protection, lost bone mass prevention, improvement of urogenital atrophy and lipidic profile and, among others. Studies have been demonstrated that some of genetic components, and mineral bone density could be, at least, accessed by detection of some genetic polymorphims such as those present at estrogen, progesterone and, vitamin D receptor. Objective: To evaluate genetic polymorphisms that could be eventually associated to hormone replacement responding to conjugated estrogen equine and its relationship to mineral bone density and FSH and LH hormone in menopause. Methods: The PCR-RFLP technique was determined to detect the presence of Estrogen Receptor Alpha (ER?) - HaeIII (Íntron 1) and MspI (Éxon 1) polymorphisms. Results: The ER? HaeIII and MspI sites gene polymorphisms, inhibited the bone mass increase after hormonal therapy (p=0.001). The HaeIII polypmorphism is related to inhibitory initial levels of FSH, before hormone replacement, whereas MspI is related to estimulatory production of FSH (p=0,000). After hormone replacement, there was an increase of FSH production in patients with HaeIII (p=0,000). The LH levels observed were the same of those FSH, i.e., the HaeIII polymorphism is related to inhibitory production of LH and, MspI polymorphism is related to estimulatory production of this (p=0,000). The women with at least one polymorphic allele HaeIII and did not to hormonal replacement suffered decline of LH and FSH production (p=0,000). Conclusion: The ER? polymorphisms HaeIII and MspI, play a major role in hormone replacement therapy.
- ItemSomente MetadadadosEffects of estrogen and estrogen-progestogen therapy on homocysteine levels and their correlation with carotid vascular resistance(Informa Healthcare-taylor & Francis, 2007-11-01) Machado, Rogerio Bonassi [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Fernandes, Cesar Eduardo [UNIFESP]; Lakryc, Eli Marcelo [UNIFESP]; Lima, Geraldo Rodrigues de [UNIFESP]; Fac Med Jundiai; Universidade Federal de São Paulo (UNIFESP); ABC Med SchObjective. To evaluate the correlation between homocysteine levels and carotid vascular resistance in menopausal women submitted to estrogen and estrogen-progestogen therapy.Methods. Eighty-six women with a mean age of 52 years were enrolled in a prospective, randomized, double-blind, 6-month study. Patients were allocated to use one of three oral therapies: placebo (n = 26), micronized estradiol 2 mg/day (n = 30) or micronized estradiol 2 mg/day plus norethisterone acetate 1 mg/day (n = 30). Evaluation of homocysteine levels and Doppler sonography of the common carotid artery, used to calculate pulsatility index (PI), were carried out prior to initiating therapy and at the end of the study. the correlation between these two parameters was evaluated using Pearson's coefficient of correlation.Results. There was a significant reduction in homocysteine levels in the groups treated with estrogen alone or estrogen combined with norethisterone. PI was significantly lower only in users of estrogen alone; however, no significant correlation was found between homocysteine measurements and PI.Conclusion. No significant correlation was found between homocysteine levels and carotid vascular resistance following hormone therapy.
- ItemSomente MetadadadosHormonal influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis(Elsevier B.V., 2007-03-20) Jarmy-Di Bella, Z. I. K.; Girao, M. J. B. C.; Di Bella, V.; Sartori, M. G. F.; Szejnfeld, J.; Baracat, E. C. [UNIFESP]; Lima, G. R.; Universidade Federal de São Paulo (UNIFESP)The lack of estrogen affects the urinary tract mainly by diminishing vascular, muscular and epithelial trophism, resulting in negative effects on continence in postmenopausal women.Objective: Study the effect of hormone therapy (estrogen and progesterone) in periurethral vessels detected by Doppler velocimetric analysis using, as parameters, the number of vessels, resistance and pulsatility indexes, as well as the minimum diastolic value.Methods: Thirty-eight postmenopausal women with stress urinary incontinence were randomized into two groups. the first consisted of women receiving 3 months of estrogen therapy previous to 3 months of continuous estrogen and progesterone combined therapy. the second comprised of women receiving 3 months of continuous estrogen and progesterone therapy. Periurethral Doppler velocimetric analysis was done before hormone administration and during treatment in both groups.Results: We observed a statistically significant increased number of periurethral vessels during treatment in both groups. There was an increase in value of the mean minimum diastolic value during estrogen and progesterone therapy in Group 2. the resistance indexes diminished in both groups. However, they were not statistically significant.Conclusion: Hormonal therapy of short duration (3-6 months) had a positive effect on the urethral continence mechanism increasing the number of periurethral vessels either with estrogen alone or combined therapy (estrogen and progesterone). (c) 2006 Elsevier Ireland Ltd. All rights reserved.
- ItemSomente MetadadadosRandomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study(Elsevier B.V., 2006-01-10) Kaari, Cristina [UNIFESP]; Haidar, Mauro Abi [UNIFESP]; Soares Junior, Jose Maria [UNIFESP]; Nunes, Marcia Gaspar [UNIFESP]; Quadros, Luis Gerk de Azevedo [UNIFESP]; Kemp, Claudio [UNIFESP]; Stavale, Joao Norberto; Baracat, Edmund Chada [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objective: the aim of this study was to evaluate the effects of isoflavone on the climacteric symptoms (Kupperman Menopausal index), vaginal pH, vaginal cytology (vaginal maturation index) and endometrium (evaluated by ultrasound and biopsy) in postmenopausal women.Methods: It was a single-center, 6-month, randomized, double-blind, estrogen-controlled trial. Seventy-nine women were randomly assigned to one of the two treatment groups: isoflavone (n = 40): 300 mg of the standardized soy extract with a medium dose of 120 mg isoflavones/day as glycoside and aglycone (60 mg twice a day), or estrogen (n = 39): one capsule of 0.625 mg conjugated equine estrogens and other capsule with glucose 0.625 mg (placebo).Results: After treatment, there was a decrease in the symptomatology in both estrogen and isoflavone groups. There was a significant decrease in vaginal pH, an increase in superficial vaginal cells and endometrium proliferation after 3 and 6 months of treatment in the estrogen group, but no differences were observed in the isoflavone group for these variables.Conclusions: We concluded that the daily standardized soy extract with 120 mg isoflavones' effect on symptoms was similar to that from estrogen. Soy isoflavone has no effect on endometrium and vaginal mucosa during the treatment. (c) 2005 Elsevier Ireland Ltd. All rights reserved.